Get the Stockscreener App
1.12
2.61%
-0.03
Pre-market:
1.14
0.02
+1.79%
Heartbeam Inc stock is traded at $1.12, with a volume of 377.71K.
It is down -2.61% in the last 24 hours and down -21.13% over the past month.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
See More
Previous Close:
$1.15
Open:
$1.12
24h Volume:
377.71K
Relative Volume:
0.16
Market Cap:
$46.02M
Revenue:
-
Net Income/Loss:
$-21.02M
P/E Ratio:
-1.7877
EPS:
-0.6265
Net Cash Flow:
$-14.59M
1W Performance:
-13.85%
1M Performance:
-21.13%
6M Performance:
-31.29%
1Y Performance:
-43.43%
1-Day Range:
$1.09
$1.15
1-Week Range:
$1.09
$1.29
52-Week Range:
$0.54
$4.00
Heartbeam Inc Stock (BEAT) Company Profile
Name
Heartbeam Inc
Sector
Industry
Phone
408-899-4443
Address
2118 WALSH AVE., SUITE 210, SANTA CLARA
Compare BEAT vs VEEV, TEM, BTSG, HQY, WAY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAT
Heartbeam Inc
|
1.12 | 46.02M | 0 | -21.02M | -14.59M | -0.6265 |
VEEV
Veeva Systems Inc
|
179.11 | 29.44B | 3.20B | 908.91M | 1.39B | 5.4168 |
TEM
Tempus Ai Inc
|
48.83 | 8.73B | 1.27B | -245.03M | -245.36M | -1.4071 |
BTSG
Brightspring Health Services Inc
|
43.31 | 8.32B | 12.91B | 104.80M | 394.69M | 0.8769 |
HQY
Healthequity Inc
|
82.10 | 6.94B | 1.31B | 215.20M | 408.32M | 2.4627 |
WAY
Waystar Holding Corp
|
24.03 | 4.61B | 1.10B | 112.09M | 283.19M | 0.6096 |
Heartbeam Inc Stock (BEAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | The Benchmark Company | Buy → Speculative Buy |
| Dec-11-25 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-08-25 | Initiated | H.C. Wainwright | Buy |
| Oct-31-25 | Initiated | Roth Capital | Buy |
| Sep-11-20 | Initiated | Needham | Buy |
| Sep-02-20 | Initiated | Robert W. Baird | Neutral |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Aug-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-26-19 | Reiterated | Dougherty & Company | Buy |
| Jul-26-18 | Reiterated | Lake Street | Buy |
| Apr-26-18 | Reiterated | The Benchmark Company | Buy |
| Feb-23-18 | Reiterated | Dougherty & Company | Buy |
| Nov-08-17 | Reiterated | Dougherty & Company | Buy |
| Oct-26-17 | Initiated | Raymond James | Outperform |
| Oct-24-17 | Initiated | SunTrust | Buy |
| Aug-09-17 | Reiterated | Dougherty & Company | Buy |
| Jul-19-17 | Reiterated | The Benchmark Company | Buy |
| Apr-11-17 | Reiterated | Dougherty & Company | Buy |
| Dec-02-16 | Initiated | Dougherty & Company | Buy |
| Sep-13-16 | Initiated | Sidoti | Buy |
| Aug-03-16 | Reiterated | The Benchmark Company | Buy |
| Jul-28-15 | Reiterated | Dougherty & Company | Buy |
| Oct-24-13 | Initiated | The Benchmark Company | Buy |
| Aug-21-13 | Initiated | Dougherty & Company | Buy |
View All
Heartbeam Inc Stock (BEAT) Latest News
HeartBeam (NASDAQ: BEAT) Reports Q3 2025 Results as FDA Review Nears Completion and Commercial Readiness Accelerates - USA Today
HeartBeam (BEAT) director receives 44,827-share stock option grant at $1.43 - Stock Titan
HeartBeam (BEAT) CFO receives stock options on 53,104 shares at $1.45 - Stock Titan
HeartBeam (BEAT) awards director Richard Ferrari 50,000 RSUs - Stock Titan
HeartBeam (BEAT) awards 41,380-share stock option grant to major holder - Stock Titan
HeartBeam (BEAT) director awarded 20,689 RSUs, holdings rise to 95,809 shares - Stock Titan
HeartBeam (BEAT) president receives 61,932-share stock option grant at $1.45 - Stock Titan
HeartBeam (BEAT) director receives 51,724 options at $1.43 exercise price - Stock Titan
HeartBeam (BEAT) director receives 17,241 RSUs in equity grant - Stock Titan
Director at HeartBeam (NASDAQ: BEAT) receives option grant for 51,724 shares - Stock Titan
HeartBeam (BEAT) president receives 55,172 stock options as equity grant - Stock Titan
Aug Opening: Can HeartBeam Inc outperform in the next rallyTrade Exit Report & Growth Oriented Trading Recommendations - baoquankhu1.vn
Heartbeam stock jumps after AI collaboration with Mount Sinai - MSN
If You Invested $1,000 in Heartbeam Inc (BEAT) - Stock Titan
HeartBeam announces first patient enrollments in heart attack detection pilot study - MSN
HeartBeam : Earnings Documents - marketscreener.com
HeartBeam (NASDAQ: BEAT) Collaborates With Mount Sinai to Advance AI-ECG Algorithm Development - USA Today
BEAT Stock Price, Quote & Chart | HEARTBEAM INC (NASDAQ:BEAT) - ChartMill
Aug Catalysts: Is HeartBeam Inc Equity Warrant benefiting from interest rate changesMarket Activity Report & Community Trade Idea Sharing - baoquankhu1.vn
Trend Recap: Is HeartBeam Inc a turnaround storyWeekly Trade Summary & Low Risk High Reward Ideas - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
H.C. Wainwright reiterates Heartbeam stock rating on commercial progress By Investing.com - Investing.com India
H.C. Wainwright reiterates Heartbeam stock rating on commercial progress - Investing.com
Heartbeam Inc reports results for the quarter ended December 31Earnings Summary - TradingView
HeartBeam Shares Fall After Benchmark Maintains Speculative Buy Rating - marketscreener.com
Benchmark Maintains HeartBeam's Rating at Speculative Buy, Price Target is $8 - marketscreener.com
HeartBeam Shares Fall After Benchmark Downgrade - marketscreener.com
HeartBeam partners with Mount Sinai to advance AI-powered ECG technology - MSN
Benchmark Downgrades HeartBeam to Speculative Buy From Buy, Price Target is $8 - marketscreener.com
HeartBeam (NASDAQ: BEAT) Reports Q4 and Full-Year 2025 Results, Advances Commercialization and Clinical Development - USA Today
HeartBeam (NASDAQ: BEAT) Announces Commercial Partnership With ClearCardio - USA Today
HeartBeam (BEAT) Q4 2025 Earnings Call Transcript - AOL.com
HeartBeam to present at March investor conferences By Investing.com - Investing.com Nigeria
HeartBeam reports net loss of USD 5.3M in Q4 2025 - Medical Buyer
HeartBeam Earnings Call Balances Breakthroughs With Cash Risk - TipRanks
HeartBeam Q4 2025 slides: FDA clearances fuel commercial launch By Investing.com - Investing.com Australia
HeartBeam (NASDAQ: BEAT) files $100M shelf; $78.8M previously registered unsold - Stock Titan
HeartBeam (BEAT) Reports Q4 and Full-Year 2025 Results, Advances Commercialization and Clinical Development - NewMediaWire
HeartBeam, Inc. (NASDAQ:BEAT) Q4 2025 Earnings Call Transcript - Insider Monkey
HeartBeam, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Precision Neuroscience, founded by Neuralink alums, is developing a competing brain implant that it says is safer - AOL.com
HeartBeam Q4 2025 slides: FDA clearances fuel commercial launch - Investing.com India
Earnings call transcript: HeartBeam Q4 2025 misses EPS, stock rises - Investing.com Nigeria
HeartBeam Q4 2025 Earnings Call Transcript - MarketBeat
HeartBeam, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BEAT) 2026-03-12 - Seeking Alpha
Heartbeam Inc Stock (BEAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.50%
2.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):